Meeting
2020 Gastrointestinal Cancers Symposium
The pretreatment lymphocyte-to-monocyte ratio (LMR) to predict treatment efficacy and prognosis in metastatic colorectal cancer treated with the combination of TAS-102 and bevacizumab (TAS-CC3 Study).
Authors
Akihisa Matsuda
Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan
Akihisa Matsuda , Yoichiro Yoshida , Hirohiko Kamiyama , Chihiro Kosugi , Hiroshi Yoshida , Keiichiro Ishibashi , Keisuke Ihara , Makoto Takahashi , Hidekazu Kuramochi , Atsuko Fukazawa , Hiromichi Sonoda , Kazuhiko Yoshimatsu , Satoru Yamaguchi , Hideyuki Ishida , Suguru Hasegawa , Takeshi Yamada , Kazuhiro Sakamoto , Keiji Koda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
000022438
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 224)
Abstract #
224
Poster Bd #
L2
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang
Poster
2018 Gastrointestinal Cancers Symposium
The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab.
First Author: Stephen John Clarke
Poster
2018 Gastrointestinal Cancers Symposium
A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial).
First Author: Hiroyuki Uetake
Poster
2015 Gastrointestinal Cancers Symposium
A multi-institutional feasibility study of S-1/oxaliplatin (SOX) plus bevacizumab in patients with advanced/metastatic colorectal cancer: HiSCO-02 prospective phase II study.
First Author: Manabu Kurayoshi